Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 9,958 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MATCH Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT03558152
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Greenville, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

NCT02312258
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Placebo, Ixazomib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

NCT02219048
View directory record Official record
Conditions
Asthma
Interventions
Placebo, PF-03715455
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

NCT01222455
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers, Pharmacokinetics, Amount of R406 in Blood
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients

NCT00876044
View directory record Official record
Conditions
Cancer
Interventions
aflibercept (AVE0005), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

NCT04657016
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Huntington Park, California • Los Angeles, California • Montclair, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

Multivirus-specific Cytotoxic T Lymphocytes (mCTL)

NCT02510404
View directory record Official record
Conditions
Refractory Viral Infections
Interventions
mCTLs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
4 Weeks to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

NCT02414958
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pilot Study of Minocycline in Huntington's Disease

NCT00277355
View directory record Official record
Conditions
Huntington Disease
Interventions
minocycline, Matching placebo
Drug
Lead sponsor
Merit Cudkowicz
Network
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Birmingham, Alabama • Englewood, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06345755
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo, Midazolam
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 5:54 AM EDT
Not listed No phase listed Observational

Biomarkers of Acute Stroke in Clinic

NCT03897478
View directory record Official record
Conditions
Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions
ISCDX blood test
Diagnostic Test
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

NCT00303485
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Placebo, Vitamin D and calcium supplementation, ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
65 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 21, 2026, 5:54 AM EDT
Recruiting Early Phase 1 Interventional

Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder

NCT06934915
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder, Autism
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Christopher John McDougle, M.D.
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

NCT04002115
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Clofarabine, Fludarabine, Busulfan, Total Body Irradiation (TBI), Cyclophosphamide, Granulocyte Colony-Stimulating Factor, Tacrolimus, Cellcept
Drug · Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 21, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

NCT06848075
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Recruiting Phase 2Phase 3 Interventional

Effects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder

NCT06559995
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Withdrawal, Ketosis
Interventions
ketone supplement "D-beta-hydroxybutryric acid and R-1,3 butanediol" 12g of ketones,, magnetic resonance imaging session, Placebo beverage
Dietary Supplement · Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

NCT00798967
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
La Jolla, California • Washington D.C., District of Columbia • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

NCT03471871
View directory record Official record
Conditions
Obstructive Sleep Apnea, Healthy Subjects
Interventions
Placebo, Lemborexant 10 mg, Lemborexant 25 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
11
States / cities
Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 21, 2026, 5:54 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Completed No phase listed Observational

Robotic-assisted Laparoscopic Sacrocolpopexy

NCT00581334
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Robotic-assisted laparoscopic sacrocolpopexy, Open sacrocolpopexy
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

NCT04568434
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 21, 2026, 5:54 AM EDT